- $11.47m
- $9.42m
- $2.29m
Brief: Femasys Inc. Q2 EPS USD -0.22
Brief: Femasys Initiates Enrollment In Pivotal Trial Of Its Permanent Birth Control Candidate Fembloc
Brief: Femasys Announces Notice Of Allowance For New U.S. Patent Application Covering Use Of FemBloc For Female Permanent Birth Control
Brief: Femasys Announces FDA Approval Of Its Ide For The Pivotal Clinical Trial Of FemBloc Permanent Birth Control, A Non-Surgical Alternative For Women
Brief: Femasys Files For Offer And Resale Of Up To 3.4 Mln Common Stock
Brief: Femasys' Ultrasound-Based Diagnostic Test Receives Product Approval In Canada
Brief: Femasys Inc Receives Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Femasys Inc. Announces Financial Results For The First Quarter Ended March 31, 2023
Brief: Femasys’Femcerv Endocervical Tissue Sampler For Cervical Cancer Diagnosis Receives Product Approval In Canada
Brief: Femasys Announces $3.9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Femasys Inc Femaseed Localized Directional Insemination For Infertility Receives Product Approval In Canada
Brief: Femasys Reports 2022 Loss Per Share Of $0.96
Brief: Femasys Held All Of Its Cash, Cash Equivalents Through Silicon Valley Bank
Brief: Femasys Inc Announces Commercial Availability Of Its Femcath Intrauterine Device
Brief: Femasys Enrollment Over 25% Complete For Femaseed De Novo Trial
Brief: Femasys Inc Provides Strategic Update On Its Femaseed Pivotal Trial Design
Femasys up on completing enrollment for birth control solution trial
Brief: Femasys Inc. Announces Enrollment Completion For Stage 2 Study Of Fembloc For Permanent Birth Control
Brief: Femasys Inc. Announces Financial Results For The Second Quarter Ended June 30, 2022 And Provides Corporate Update